STOCK TITAN

BioNexus Gene Lab (BGLC) SEC Filings, Apr-Aug 2026

BGLC NASDAQ

BioNexus Gene Lab Corp. filings document material-event disclosures for its precision diagnostics strategy, subsidiary governance, capital structure, and periodic reporting obligations. Recent 8-K filings cover VitaGuard™ MRD commercialization activity, the Fidelion Diagnostics relationship, Chemrex governance restructuring, strategic partnership disclosures, and exhibits tied to company press releases and material agreements.

The company’s filing record also includes Form 12b-25 notifications for delayed periodic reports, with explanations tied to financial-reporting transitions and enhanced transaction review. Capital-structure disclosures include registration and equity financing arrangements, while governance disclosures address parent-level oversight, subsidiary board accountability, reporting protocols, and reporting-control processes.

Rhea-AI Summary

FIDELION DIAGNOSTICS PTE. LTD. is identified as a greater than 5% holder of BioNexus Gene Lab Corp and reports direct ownership of 392,329 shares of common stock. This Form 3 serves as an initial statement of holdings and does not report any specific purchase or sale transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
insider
-
Rhea-AI Summary

BioNexus Gene Lab Corp disclosed that CEO and director Tan Lee Su-Leng filed a Form 3 reporting her holdings of company equity securities. The report lists 0.0000 shares held directly following a holdings entry dated 2023-08-15, with no buy or sell transactions shown.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
insider
-
Rhea-AI Summary

BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul reports direct ownership of 0 shares of common stock as of 2023-12-11. The entry is presented as a holding record, with no purchase, sale, or derivative transactions reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
insider
Rhea-AI Summary

BioNexus Gene Lab Corp reports initial insider holdings for director Yap Chee Keong. The disclosure lists a holding entry for common stock with 0.0000 shares owned directly as of the reported date, indicating no reportable direct equity position in the company’s common stock at that time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
insider
-
Rhea-AI Summary

BioNexus Gene Lab Corp reports initial insider holdings for director Low Jook Yuen. The filing shows beneficial ownership of 1,261 shares of common stock, held directly. This Form 3 establishes the director’s reported equity position as an insider of the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
insider
-
Rhea-AI Summary

BioNexus Gene Lab Corp executive Chong Set Fui, the company's CFO, filed an initial statement of beneficial ownership. The filing reports 0 shares of BioNexus Gene Lab Corp common stock owned directly as of 2025-06-17, with no reported purchases, sales, or derivative positions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
insider
Rhea-AI Summary

BioNexus Gene Lab Corp. outlines continued progress toward commercializing the VitaGuard™ molecular residual disease (MRD) liquid‑biopsy platform in Southeast Asia after a working visit to Tongshu Gene facilities in Shanghai and Changzhou, where VitaGuard is in paid commercial use at numerous hospitals in China.

VitaGuard is a tumor‑naive, fixed‑panel next‑generation sequencing test for detecting circulating tumor DNA associated with MRD in solid tumors, designed to simplify repeat blood‑based monitoring. BioNexus holds exclusive rights for VitaGuard‑based products and services in ten Southeast Asian markets and owns approximately 15% of Fidelion Diagnostics, which holds VitaGuard intellectual‑property rights outside China.

Management has previously indicated an expected VitaGuard cost per test of under US$300, and the ten licensed markets together have a population of more than 680 million people. Following the visit, BioNexus and Fidelion are working on documentation transfer, local verification and validation, and regulatory and commercial preparations in Malaysia and Singapore, targeting initial deployment in selected regional medical hubs during 2026, subject to completion of this work and applicable approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
current report
-
Rhea-AI Summary

BioNexus Gene Lab Corp. highlighted its role in the 2026 China–Malaysia Economic Cooperation Outlook Forum, where CEO Sam Tan advocated moving Malaysia–China biotechnology ties beyond simple trade and toward co-development, clinical validation, and regional commercialization.

The company described a Malaysia-based ASEAN “execution hub” model using examples such as Fidelion Diagnostics and the VitaGuard™ MRD platform, linking China-origin biotechnology with international commercialization vehicles, clinical validation, and regulatory discipline. BioNexus emphasized precision diagnostics, liquid biopsy, minimal residual disease monitoring, and AI-assisted healthcare, and outlined collaboration pillars including accelerated validation of China-origin precision oncology tools, infrastructure for scalable labs, and AI-integrated healthcare that respects regional data sovereignty and privacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
current report
-
Form 10-Q
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
quarterly report
Form 10-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
annual report

FAQ

How many BioNexus Gene Lab (BGLC) SEC filings are available on StockTitan?

StockTitan tracks 32 SEC filings for BioNexus Gene Lab (BGLC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BioNexus Gene Lab (BGLC)?

The most recent SEC filing for BioNexus Gene Lab (BGLC) was filed on November 16, 2026.